- Cellex Cell Professionals has expanded its GMP-certified facility to over 2,500 m², now supporting 43% cleanroom space across 37 workstations.
- The company has delivered more than 5,800 CGT/ATMP batches and recently added two new clients to its growing pipeline.
Cellex Cell Professionals, a European Contract Development and Manufacturing Organization (CDMO) focused on Cell & Gene Therapy (CGT), has announced the expansion of its GMP-certified manufacturing site. The facility now comprises more than 2,500 m², with 43% allocated to cleanroom space and 37 dedicated workstations.
Founded in 2001 in Dresden, Cellex began by supporting allogeneic blood stem cell transplantation. It has since grown into a full-service CDMO, performing over 50,000 cell collections and transporting more than 20,000 cellular shipments globally. Since 2018, the company has also supplied GMP-grade starting materials for clinical trials and commercial programs.
Cellex has delivered over 5,800 CGT/ATMP batches, including more than 1,300 for clinical use and over 4,500 for commercial purposes. The company supports the commercial production of three CAR-T therapies approved in the EU and manufactured Europe’s first allogeneic CAR-T product in 2023.
“In the manufacturing of advanced therapies, innovation must be matched by a high degree of precision and reliability,” said Carla Kreissig, Managing Director and Chief Medical Officer of Cellex. “Reaching over 5,800 batches reflects not just scale – but deep process maturity and trust from our partners.”
The company has also opened a new materials warehouse to enhance batch safety, quality, and efficiency. With two new clients onboarded in January 2025 and a pipeline of new mandates, Cellex continues to expand its role in the European CGT landscape.
